Study guide
13.1 Product Accountability and Adherence Calculations
ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Format, Eligibility and Registration
1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions
2 Chapter 2: CRA Responsibilities and Study Planning
2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy
3 Chapter 3: Protocols, Endpoints and Trial Design
3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs
4 Chapter 4: Bias Control, Blinding and Product Information
4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates
5 Chapter 5: Estimands and Device Instructions
5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training
6 Chapter 6: Ethical Foundations and Independent Oversight
6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review
7 Chapter 7: Ethics Communication and Informed Consent
7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates
8 Chapter 8: Recruitment, Retention and Confidentiality
8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access
9 Chapter 9: Safety Definitions and Classification
9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information
10 Chapter 10: Safety Detection, Reporting and Oversight
10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight
11 Chapter 11: Follow-Up, Adherence and Conflicts
11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments
12 Chapter 12: Development Stages and Product Management
12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response
13 Chapter 13: Accountability, Integrity and Regulatory Status
13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting
14 Chapter 14: Current GCP Principles and Delegation
14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority
15 Chapter 15: Oversight, Protocol Control and Amendments
15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution
16 Chapter 16: Implementation and Trial Responsibilities
16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles
17 Chapter 17: Quality Planning, Root Causes and CAPA
17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification
18 Chapter 18: Risk Assessment and Monitoring Methods
18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review
19 Chapter 19: Quality Metrics, Plans and Communication
19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication
20 Chapter 20: Site Qualification and Readiness
20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release
21 Chapter 21: Initiation, Equipment and Supplies
21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies
22 Chapter 22: Samples, Diagnostics and Financial Feasibility
22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility
23 Chapter 23: Interim Monitoring and Reporting
23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports
24 Chapter 24: Essential Records, Audits and Findings
24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning
25 Chapter 25: Close-Out, Retention and Destruction
25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access
26 Chapter 26: Source Records and Good Documentation
26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context
27 Chapter 27: Electronic Systems, Metadata and Queries
27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning
28 Chapter 28: Dataset Finalisation and Critical Data
28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings
13.1 Product Accountability and Adherence Calculations
Key Takeaways Explain This Topic AI
Site-stock accounting separates dispensing, participant returns and final disposition.
Return-based adherence uses the protocol-defined expected amount, including relevant holds.
A note to file cannot by itself establish the location of missing product.
Last updated: October 2026
Product Accountability and Adherence Calculations
The Master Drug Accountability Log tracks aggregate product inventory at the site level, documenting:
Protocol number, investigative site number, and Principal Investigator name.
Product trade or code name, dosage form, and strength.
Lot or batch numbers, kit identification serial numbers, and shipment tracking numbers.
Date of shipment receipt and physical condition of containers upon delivery.
Total quantity received, cumulative balance on hand, and initials of the authorized recipient.
The Subject Dispensing Log
The Subject Dispensing Log records individual subject exposure, documenting:
Subject screening/randomization identification number and subject initials.
Date of dispensing and visit number (e.g., Visit 2 / Week 4).
Kit number(s) dispensed and number of dosage units (tablets, capsules, or vials) provided.
Dose prescribed and dose modification details.
Date the subject returned empty, partially used, or unused containers.
Quantity of dosage units returned by the subject.
Signature or initials of the dispensing pharmacist or authorized study coordinator.
Estimating participant adherence without confusing inventory
For a simple fixed-tablet regimen, an illustrative estimate is (units dispensed minus units returned) / units expected to be taken × 100% . This estimates disappearance from the participant's supply, not observed ingestion. Record lost tablets, hospital doses, partial containers and interruptions before interpreting the result. Protocol-specific rules determine the expected dose count and how to address non-adherence; 80–120% is not a universal GCP acceptance range.
Example: 60 tablets were dispensed for 30 days at two tablets daily. A documented three-day medical hold reduces expected use to 54 tablets. Nine tablets are returned, so 51 are unreturned: 51/54 × 100 = 94.4% , rounded to one decimal. If the site instead divides by 60, it obtains 85.0% and ignores the authorised interruption. Both calculations can be arithmetically correct for different denominators, but only the protocol-defined denominator answers the intended question.
For devices, preserve model/configuration, lot/serial identifiers and participant-use traceability as required by the protocol and instructions. A malfunction, use error or labelling issue needs documented assessment even when no injury occurred. Follow the study's escalation and return instructions. Do not clean or alter an explant in a way that destroys evidence; clinical safety, biosafety and the specified investigation process control its handling.
Do not infer a universal UDI requirement or 24–48-hour device deadline from ICH medicinal-product guidance.
CRA IP Reconciliation Responsibilities: The Triangulation Method
During routine interim and close-out monitoring visits, the CRA does not merely glance at pharmacy logbooks. The CRA must execute a rigorous, three-way Triangulation Audit Methodology :
Triangulation Audit Steps
Physical Inventory Audit: The CRA physically counts all unopened kits, intact blister cards, vials, returned empty bottles, and partially used boxes stored in the pharmacy or research storage room.
Log Verification: The CRA compares the physical count directly against the Master DAL and Subject Dispensing Logs, verifying mathematical totals and unit balances.
Source and EDC Cross-Check: The CRA cross-checks dispensed kit IDs against doctor progress notes, nursing administration records, electronic Case Report Forms (eCRFs), and Interactive Response Technology (IRT) records to confirm that the correct kit was dispensed to the correct randomized participant.
Resolving Discrepancies and Missing Product
If a discrepancy is identified (e.g., two tablets missing, broken vial, unreturned bottle):
The CRA must never quietly adjust numbers or alter logs.
The CRA must interview pharmacy personnel, trace physical disposal receptacles, and audit subject visit charts.
Document the investigation, evidence, conclusion and follow-up through the applicable controlled records.
If investigational product was dispensed incorrectly (wrong dose or wrong randomized kit), the event must be reported as a major protocol deviation to the sponsor and IRB.
Closing the accountability record
Use mutually exclusive categories for final disposition. One useful site-stock balance is:
Opening site stock + receipts + participant returns = dispensing + depot returns + authorised destruction + closing site stock + documented losses.
A participant-returned tablet enters stock again; it is not also counted as consumed. Keep dispensing and participant administration separate. Example: the site receives 200 tablets, dispenses 120, receives 20 back, and returns 100 to the depot. The balance is 200 + 20 = 120 + 100, with zero closing stock.
Participant-level records separately explain the 100 tablets not returned. An equation that adds all 120 dispensed tablets and all 100 depot-returned tablets against only 200 received would double-count the 20 tablets returned by participants.
Verify discrepancies and their supporting evidence, preserve traceability, and follow sponsor-authorised return or destruction procedures. A note to file may document an investigation but cannot prove the location of missing product. Do not alter accountability totals to force balance or discard unexplained containers before review. A destruction record identifies the product, quantities and disposition under the authorised procedure.
Official sources
Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , ICH E8(R1) , ACRP CCRA Exam Content Outline .